310210 - Voronoi, Inc.

310210 Summary

Biopharma

Stock Price & Overview

₩153,000 +5,800 (+3.94%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩153,000 ≈ US$109 · Market cap ₩2.8tn (≈ $2.0bn)

310210 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Revenue	7.5	0.0	0.0	9.8	14.8	6.2
Operating Income	-54.4	-36.3	-31.3	-17.9	-10.8	-27.0
Finance Income	9.8	5.0	4.5	1.8	0.9	0.9
Finance Costs	6.0	1.2	5.2	3.4	1.7	0.8
Pretax Income	-50.6	-32.6	-36.2	-19.4	-15.8	-27.1
Income Tax Expense	-7.9	-0.0	0.7	-0.5	0.2	0.6
Net Income	-42.7	-32.6	-36.8	-19.9	-15.6	-26.5
Total Comprehensive Income	-42.0	-32.3	-35.1	-23.4	-22.9	-24.5

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	171.2	73.7	94.7	64.0	40.2	47.7
Current Assets	148.3	56.5	61.3	49.2	18.7	13.0
Cash & Cash Equivalents	35.7	10.2	12.9	11.0	18.2	11.9
Trade Receivables	0.0	0.0	0.0	—	—	—
Non-current Assets	22.9	17.2	33.4	14.8	21.5	34.7
Property, Plant & Equipment	6.2	5.4	5.4	6.4	8.2	10.0
Intangible Assets	0.8	1.0	0.9	5.2	5.8	13.0
Total Liabilities	67.4	7.2	13.3	29.7	33.2	19.1
Current Liabilities	7.9	6.8	12.5	13.8	18.1	18.4
Non-current Liabilities	59.5	0.5	0.8	15.9	15.1	0.7
Total Equity	103.8	66.4	81.3	34.3	6.9	28.6
Share Capital	9.2	9.2	8.7	6.3	5.7	5.3
Retained Earnings	-232.2	-189.5	-156.9	-120.1	-100.2	-85.1

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Cash from Operating Activities	-72.1	-29.1	-28.8	-16.3	-17.6	-15.9
Cash from Investing Activities	-32.5	22.3	-32.2	-38.0	-0.6	0.1
Purchase of Property, Plant & Equipment	1.6	1.1	1.1	0.5	0.6	0.4
Cash from Financing Activities	130.2	3.9	63.0	47.1	24.4	26.7
Net Change in Cash	25.6	-2.8	1.9	-7.3	6.1	10.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	0.0	0.0	0.0	4.1	3.4	0.0	0.0	0.0	0.0	0.0
Operating Income	-29.3	-22.0	-16.2	-13.6	-10.2	-14.5	-10.6	-9.5	-8.6	-7.6
Finance Income	1.7	2.7	7.8	0.9	0.4	0.6	2.0	0.3	1.2	1.4
Finance Costs	1.4	2.7	3.8	1.2	0.8	0.3	0.2	0.3	0.3	0.4
Pretax Income	-29.0	-22.0	-12.2	-13.8	-10.5	-14.1	-8.9	-9.4	-7.7	-6.6
Income Tax Expense	0.0	0.0	-7.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income	-29.0	-22.0	-4.3	-13.8	-10.5	-14.1	-8.9	-9.4	-7.7	-6.6
Total Comprehensive Income	-29.2	-20.5	-4.9	-12.7	-9.2	-15.2	-9.0	-8.4	-10.2	-4.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	133.7	158.8	171.2	99.6	51.4	61.8	73.7	82.3	85.0	93.7
Current Assets	107.2	131.8	148.3	74.3	33.5	44.9	56.5	65.1	62.2	68.9
Cash & Cash Equivalents	24.8	13.5	35.7	8.5	15.0	8.2	10.2	15.1	7.2	11.1
Trade Receivables	0.0	0.0	0.0	—	—	—	—	—	—	—
Non-current Assets	26.5	26.9	22.9	25.3	17.8	16.9	17.2	17.3	22.8	24.9
Property, Plant & Equipment	9.7	7.9	6.2	6.1	6.0	6.2	5.4	5.5	5.1	5.2
Intangible Assets	0.8	0.8	0.8	1.0	1.0	1.0	1.0	0.9	0.9	0.9
Total Liabilities	64.5	66.9	67.4	46.4	4.7	8.8	7.2	7.8	16.0	15.4
Current Liabilities	11.3	11.8	7.9	4.7	4.2	8.3	6.8	7.3	15.0	14.7
Non-current Liabilities	53.2	55.1	59.5	41.6	0.5	0.5	0.5	0.5	1.0	0.7
Total Equity	69.2	91.9	103.8	53.2	46.6	53.0	66.4	74.5	69.0	78.4
Share Capital	9.2	9.2	9.2	9.2	9.2	9.2	9.2	9.2	8.9	8.9
Retained Earnings	-283.2	-254.2	-232.2	-227.9	-214.1	-203.6	-189.5	-180.6	-171.2	-163.5

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-23.5	-14.3	-36.4	-13.9	-10.9	-10.9	-9.3	-8.3	-7.1	-4.4
Cash from Investing Activities	34.5	-7.5	-16.3	-42.6	18.0	8.5	3.9	14.6	2.8	1.0
Purchase of Property, Plant & Equipment	2.2	1.6	0.4	0.3	0.2	0.8	0.7	0.2	0.2	0.1
Cash from Financing Activities	0.4	-0.6	80.0	49.9	-0.1	0.4	0.3	1.8	0.3	1.5
Net Change in Cash	11.4	-22.3	27.3	-6.7	6.9	-2.0	-5.1	8.1	-3.9	-1.9

Consolidated (CFS), from DART. 6 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

310210 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	7.5	—	-8.4%	+4.0%	—
Operating income	-54.4	—	—	—	—
Net income	-42.7	—	—	—	—
EPS	₩-2,306	—	—	—	—
Operating cash flow	-72.1	—	—	—	—
Shareholders' equity	103.8	+56.3%	+44.7%	+29.4%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

310210 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Operating margin	-723.9%	—	—	-182.9%	-73.2%	-437.2%
Net margin	-568.5%	—	—	-203.7%	-105.3%	-428.7%
Return on equity	-50.2%	-44.1%	-63.8%	-96.7%	-87.7%	-92.6%
Return on assets	-34.9%	-38.8%	-46.5%	-38.2%	-35.4%	-55.5%
Operating cash flow / revenue	-959.7%	—	—	-167.2%	-119.3%	-257.2%
Capex / revenue	22.0%	—	—	5.6%	3.9%	6.1%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 310210

Symbol	Last Price
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%
237690ST Pharm Co., Ltd.	₩101,200 +2.2%
226950Olix Pharmaceuticals, Inc.	₩95,900 +4.5%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.